25th May 2011 11:08
| |||||||||||||||||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Sinclair Pharma Plc GB0033856740 | ||||||||||||||||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||||||||||||||||
An acquisition or disposal of voting rights | |||||||||||||||||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||||||||||||||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||||||||||||||||
An event changing the breakdown of voting rights | X | ||||||||||||||||||
Other (please specify): | |||||||||||||||||||
3. Full name of person(s) subject to thenotification obligation: iii | Norges Bank | ||||||||||||||||||
4. Full name of shareholder(s) (if different from 3.):iv | N/A | ||||||||||||||||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 23rd May 2011 | ||||||||||||||||||
6. Date on which issuer notified: | 25th May 2011 | ||||||||||||||||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 6%, 5% and 4% | ||||||||||||||||||
8. Notified details: | |||||||||||||||||||
A: Voting rights attached to shares viii, ix | |||||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | |||||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||||||||||
GB0033856740 |
14,926,946
| 14,926,946 |
14,926,946
| 14,926,946 | 3.92% | ||||||||||||||
B: Qualifying Financial Instruments | |||||||||||||||||||
Resulting situation after the triggering transaction | |||||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | |||||||||||||||
N/A | N/A | N/A | N/A | N/A | |||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||||||||||||||
Resulting situation after the triggering transaction | |||||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| ||||||||||||||
N/A | N/A | N/A | N/A |
N/A
| Nominal | Delta | |||||||||||||
N/A | N/A | ||||||||||||||||||
Total (A+B+C) | |||||||||||||||||||
Number of voting rights | Percentage of voting rights | ||||||||||||||||||
14,926,946 | 3.92% | ||||||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | |||||||||||||||||||
N/A | |||||||||||||||||||
Proxy Voting: | |||||||||||||||||||
10. Name of the proxy holder: | Norges Bank | ||||||||||||||||||
11. Number of voting rights proxy holder will ceaseto hold: | N/A | ||||||||||||||||||
12. Date on which proxy holder will cease to holdvoting rights: | N/A | ||||||||||||||||||
13. Additional information: | None | ||||||||||||||||||
14. Contact name: | Jonas Lexmark | ||||||||||||||||||
15. Contact telephone number: | +47 2407 3134 | ||||||||||||||||||
Related Shares:
Sinclair Pharma